Indeed, anti-CD137 plus anti-PD-1 resulted in increased efficacy in mouse models for colon carcinoma (ID8), melanoma (B16F10), and ovarian carcinoma (ID8) (117, 120, 121). This evidence concerns the gene TNFRSF9 and colon carcinoma.